MBio Diagnostics is developing a portfolio of point-of-care tests for medical settings where lab-quality results are vital in making time-critical decisions. We have active product development programs in COVID-19, host-response biomarkers and cardiac markers.
The LightDeck® platform was designed to meet customer requirements:
- Quality: Highly sensitive tests that deliver lab-quality results
- Quick: Actionable data in 5-15 minutes with a simple procedure
- Quantitative: More than yes/no to inform treatment decisions
- Multiplex: Multiple tests per sample plus internal quality control to maximize confidence in results
The LightDeck COVID-19 Total Antibody Test is to determine past SARS-CoV-2 infection and potential immunity.
Host-response biomarkers in acute infection can help stage patients and inform treatment decisions.
We are developing a NextGen test for heart attack: a high-sensitivity troponin test and a 3-plex Cardiac Panel.
Products are under development and not available for sale.